1. Bluebird Bio. A study evaluating the efficacy and safety of the LentiGlobin® BB305 drug product in participants with transfusion-dependent β-thalassemia, who do not have a β0/β0 genotype. ClinicalTrials.gov. 2022. https://www.clinicaltrials.gov/ct2/show/NCT02906202?term=NCT02906202&draw=2&rank=1. Accessed 22 Apr 2022.
2. Bluebird Bio. A study evaluating the efficacy and safety of the LentiGLobin BB305 drug rpoduct in participants with transfusion-dependent B-thalassemia. 2022. https://www.clinicaltrials.gov/ct2/show/NCT03207009?term=NCT03207009&draw=2&rank=1. Accessed 22 Apr 2022.
3. Bluebird Bio. A study evaluating gene therapy with BB305 lentiviral vector in sickle cell disease. ClinicalTrials.gov. 2022. https://clinicaltrials.gov/ct2/show/NCT04293185?term=NCT04293185&draw=2&rank=1. Accessed 22 Apr 2022.
4. Orchard Therapeutics. A clinical study to enable process validation of commercial grade OTL-101. ClinicalTrials.gov. 2021. https://clinicaltrials.gov/ct2/show/NCT04140539?term=NCT04140539&draw=2&rank=1. Accessed 22 Apr 2022.
5. Orchard Therapeutics. Gene therapy for Wiskott–Aldrich syndrome (TIGET-WAS). ClinicalTrials.gov. 2021. https://clinicaltrials.gov/ct2/show/NCT01515462?term=NCT01515462&draw=2&rank=1. Accessed 22 Apr 2022.